UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 20, 2009

Colfax Corporation

(Exact name of registrant as specified in its charter)

Delaware (State or other jurisdiction of incorporation) **001-34045** (Commission File Number) **54-1887631** (I.R.S. Employer Identification No.)

8730 Stony Point Parkway, Suite 150 Richmond, VA 23235 (Address of Principal Executive Offices) (Zip Code)

(804) 560-4070

(Registrant's telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 2.02. Results of Operations and Financial Condition.

On February 20, 2009, Colfax Corporation issued a press release reporting financial results for the quarter and the year ended December 31, 2008. A copy of Colfax Corporation's press release is attached to this report as Exhibit 99.1 and is incorporated in this report by reference. Colfax Corporation has scheduled a conference call for 8:00 a.m. EST on February 20, 2009 to discuss its financial results, and slides for that call are attached to this report as Exhibit 99.2 and are incorporated in this report by reference.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

| 99.1 | Colfax Corporation press release dated February 20, 2009, reporting financial results for the quarter and the year ended December 31, 2008. |
|------|---|
| | |

99.2 Colfax Corporation slides for February 20, 2009 conference call for financial results for the quarter and the year ended December 31, 2008.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Colfax Corporation

Date: February 20, 2009

 By:
 /s/ JOHN A. YOUNG

 Name:
 John A. Young

 Title:
 President and Chief Executive Officer

EXHIBIT INDEX

- 99.1 Colfax Corporation press release dated February 20, 2009, reporting financial results for the quarter and the year ended December 31, 2008.
- 99.2 Colfax Corporation slides for February 20, 2009 conference call for financial results for the quarter and the year ended December 31, 2008.

COLFAX REPORTS FOURTH QUARTER, FULL-YEAR 2008 RESULTS

Record Sales and Orders Drive Strong Performance in 2008

RICHMOND, VA – February 20, 2009 - Colfax Corporation (NYSE: CFX), a global leader in engineered fluid handling products and systems, today announced financial results for the fourth quarter and full year ended December 31, 2008. On a year-over-year basis, highlights for the quarter and the year include:

Fourth quarter of 2008 (all comparisons versus the fourth quarter of 2007)

- Net income of \$10.4 million (24 cents per share basic and diluted); Adjusted net income (as defined below) of \$17.5 million (40 cents per share), an increase of 19.1%
- Net sales of \$159.3 million, an increase of 10.9%; Organic sales growth (as defined below) of 19.1%
- Operating income of \$21.7 million; Adjusted operating income (as defined below) of \$28.6 million, an increase of 14.9%
- EBITDA (as defined below) of \$25.2 million; Adjusted EBITDA (as defined below) of \$32.1 million, an increase of 10.8%
- Fourth quarter orders of \$126.3 million, a decrease of 19.3%; Organic order decline (as defined below) of 15.8%
- Backlog of \$337.3 million at period end

Full year 2008 (all comparisons versus 2007)

- Net loss of \$0.6 million (11 cents per share basic and diluted); Adjusted net income (as defined below) of \$53.7 million (\$1.22 per share), an increase of 32.8%
- Net sales of \$604.9 million, an increase of 19.5%; Organic sales growth (as defined below) of 13.9%
- Operating income of \$16.7 million; Adjusted operating income (as defined below) of \$90.8 million, an increase of 24.5%
- EBITDA (as defined below) of \$31.5 million; Adjusted EBITDA (as defined below) of \$105.6 million, an increase of 19.8%
- Record orders for the year of \$669.2 million, an increase of 15.1%; Organic order growth (as defined below) of 7.0%

Adjusted net income, adjusted net income per share, adjusted operating income, EBITDA, adjusted EBITDA, organic sales growth and organic order growth are not financial measures calculated in accordance with generally accepted accounting principles in the U.S. ("GAAP"). See below for a description of the measures' usefulness and a reconciliation of these measures to their most directly comparable GAAP financial measures.

"We had an excellent fourth quarter," said John Young, president and CEO of Colfax Corporation. "Our strong results were driven by organic sales growth of 19% and a 210 basis point improvement in gross profit margin. We also delivered record results for the year, including organic sales growth of 14%, in line with our low double-digit growth expectation. Sales growth was lead by increased demand in the power generation, commercial marine and general industrial end markets. We are well positioned heading into 2009, with a higher backlog than we had at the beginning of 2008."

He continued, "Despite our recent performance and our relatively strong backlog, we expect that the second half of the year could be very challenging if current economic conditions persist. We remain cautious on our outlook but continue to expect organic sales growth in the range of 1% to 3% and adjusted earnings per share of \$1.10 to \$1.17 for 2009. Our focus continues to be on growing the business through expanding our served markets, executing on our breakthrough initiatives and pursuing acquisitions while controlling costs. Our strong financial position allows us to be flexible as well as opportunistic. We believe that the long-term fundamentals of our end markets including the need for infrastructure and energy worldwide bode well for our fluid-handling products and solutions."

Non-GAAP Financial Measures

Colfax has provided in this press release financial information that has not been prepared in accordance with GAAP. These non-GAAP financial measures are adjusted net income, adjusted net income per share, adjusted operating income, EBITDA, adjusted EBITDA, organic sales growth and organic order growth. Adjusted net income, adjusted net income per share, adjusted operating income and adjusted EBITDA exclude asbestos liability and defense cost (income) and asbestos coverage litigation expense, certain legacy legal charges, certain due diligence costs, as well as one time initial public offering-related costs. Adjusted net income also reflects interest expense as if the initial public offering (IPO) had occurred at the beginning of 2007 and presents income taxes at an effective tax rate of 34%. Adjusted net income per share assumes the 44,006,026 shares outstanding at the closing of the IPO to be outstanding since January 1, 2007. Organic sales growth and organic order growth exclude the impact of acquisitions and foreign exchange rate fluctuations. These non-GAAP financial measures assist Colfax in comparing its operating performance on a consistent basis because, among other things, they remove the impact of changes in our capital structure and asset base, non-recurring items such as IPO-related costs, legacy asbestos issues (except in the case of EBITDA) and items outside the control of its operating management team.

Non-GAAP financial measures should not be considered in isolation from, or as a substitute for, financial information calculated in accordance with GAAP. Investors are encouraged to review the reconciliation of these non-GAAP measures to their most directly comparable GAAP financial measures. A reconciliation of non-GAAP financial measures presented above to GAAP results has been provided in the financial tables included in this press release.

Conference Call and Webcast

Colfax will host a conference call to provide details about its results and business strategy on Friday, February 20 at 8:00 a.m. EST. The call will be open to the public through 719-325-4744 or 877-723-9518 and webcast via Colfax's website at <u>http://www.colfaxcorp.com</u> under the "Investor Relations" section. Access to a supplemental slide presentation can also be found at the Colfax website under the same heading. Both the audio of this call and the slide presentation will be archived on the website later today and will be available until the next quarterly call. In addition, a replay of this call will be available until approximately March 6, 2009. The replay number in the U.S. is 888-203-1112 and internationally it is 719-457-0820, and the access code is 4053059.

About Colfax Corporation

Colfax Corporation is a global leader in critical fluid-handling solutions, including the manufacture of positive displacement industrial pumps and valves used in global oil & gas, power generation, marine, naval and a variety of other industrial applications. Key product brands include Allweiler, Fairmount Automation, Houttuin, Imo, LSC, Portland Valve, Tushaco, Warren and Zenith. Colfax is traded on the NYSE under the ticker "CFX." Additional information about Colfax's products, businesses and practices is available at <u>www.colfaxcorp.com</u>

Cautionary Note Concerning Forward Looking Statements

This press release contains forward-looking statements, including forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements concerning Colfax's plans, objectives, expectations and intentions and other statements that are not historical or current facts. Forward-looking statements are based on Colfax's current expectations and involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such forward-looking statements. Factors that could cause Colfax's results to differ materially from current expectations include, but are not limited to factors detailed in Colfax's reports filed with the U.S. Securities and Exchange Commission as well as its Registration Statement on Form S-1 under the caption "Risk Factors". In addition, these statements are based on a number of assumptions that are subject to change. This press release speaks only as of this date. Colfax disclaims any duty to update the information herein.

COLFAX CORPORATION CONSOLIDATED STATEMENTS OF OPERATIONS Unaudited

(amounts in thousands, except per share data)

| | | Three Months Ended | | | | | Year Ended | | | | |
|---|-----|----------------------|----|----------------------|----|--------------------|------------|--------------------|--|--|--|
| | Dec | December 31, 2008 | | December 31, 2007 | | cember 31, 2008 | De | cember 31, 2007 | | | |
| Net sales | \$ | 159,311 | \$ | 143,703 | \$ | 604,854 | \$ | 506,305 | | | |
| Cost of sales | | 101,557 | | 94,488 | | 387,667 | | 330,714 | | | |
| | | | | | | | | | | | |
| Gross profit | | 57,754 | | 49,215 | | 217,187 | | 175,591 | | | |
| Initial public offering-related costs | | - | | - | | 57,017 | | - | | | |
| Selling, general and administrative expenses | | 27,718 | | 23,223 | | 125,234 | | 98,500 | | | |
| Research and development expenses | | 1,426 | | 1,087 | | 5,856 | | 4,162 | | | |
| Asbestos liability and defense (income) costs | | 1,978 | | (31,946) | | (4,771) | | (63,978) | | | |
| Asbestos coverage litigation expenses | | 4,905 | | 5,314 | | 17,162 | _ | 13,632 | | | |
| | | | | | | | | | | | |
| Operating income | | 21,727 | | 51,537 | | 16,689 | | 123,275 | | | |
| Interest expense | | 2,138 | | 4,830 | | 11,822 | | 19,246 | | | |
| Income before income taxes | | 19,589 | | 46,707 | | 4,867 | | 104,029 | | | |
| Provision for income taxes | | 9,210 | | 17,715 | | 5,438 | | 39,147 | | | |
| | | | | - ,, | - | -, | | | | | |
| Net income (loss) | \$ | 10,379 | \$ | 28,992 | \$ | (571) | \$ | 64,882 | | | |
| | | | | | | | | | | | |
| Net income (loss) available to common | | | | | | | | | | | |
| shareholders per share—basic and diluted | \$ | 0.24 | \$ | 0.77 | \$ | (0.11) | \$ | 1.79 | | | |
| | | | | | | | | | | | |

COLFAX CORPORATION CONDENSED CONSOLIDATED BALANCE SHEETS

Preliminary and Unaudited (amounts in thousands)

| | | | December 31, | | |
|---|------|---------|--------------|---------|--|
| | 2008 | | | 2007 | |
| ASSETS | | | | | |
| CURRENT ASSETS: | | | | | |
| Cash and cash equivalents | \$ | 28,762 | \$ | 48,093 | |
| Trade receivables, less allowance for doubtful accounts | | 101,064 | | 84,430 | |
| Inventories, net | | 80,327 | | 68,287 | |
| Asbestos insurance asset | | 26,473 | | 19,059 | |
| Asbestos insurance receivable | | 36,371 | | 44,664 | |
| Other current assets | | 21,860 | | 22,534 | |
| Total current assets | | 294,857 | | 287,067 | |
| Deferred income taxes, net | | 53,428 | | 36,447 | |
| Property, plant and equipment, net | | 92,090 | | 88,391 | |
| Goodwill and intangible assets, net | | 179,046 | | 185,353 | |
| Long-term asbestos insurance asset | | 277,542 | | 286,169 | |
| Deferred loan costs, pension and other assets | | 16,113 | | 13,113 | |
| Total assets | \$ | 913,076 | \$ | 896,540 | |
| LIABILITIES AND SHAREHOLDERS' EQUITY | | | | | |
| CURRENT LIABILITIES: | | | | | |
| Current portion of long-term debt and capital leases | \$ | 5,420 | \$ | 2,640 | |
| Accounts payable | | 52,138 | | 48,910 | |
| Accrued asbestos liability | | 28,574 | | 28,901 | |
| Other accrued liabilities | | 68,154 | | 67,923 | |
| Total current liabilities | | 154,286 | | 148,374 | |
| Long-term debt, less current portion | | 91,701 | | 203,853 | |
| Long-term dividend payable to shareholders | | - | | 35,054 | |
| Long-term asbestos liability | | 328,684 | | 347,332 | |
| Pension and accrued post-retirement benefits | | 130,188 | | 71,365 | |
| Other liabilities | | 41,286 | | 37,511 | |
| Total liabilities | | 746,145 | _ | 843,489 | |
| Shareholders' equity | | 166,931 | | 53,051 | |
| Total liabilities and shareholders' equity | \$ | 913,076 | \$ | 896,540 | |

COLFAX CORPORATION CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

Preliminary and Unaudited (amounts in thousands)

| | Year ended December 31 | | |
|---|------------------------|-------|--|
| | 2008 | 2007 | |
| ash flows from operating activities: | | | |
| et (loss) income | \$ (571) \$ | 64,88 | |
| djustments to reconcile net (loss) income to cash (used in) provided by operating activities: | | | |
| Depreciation and amortization | 14,788 | 15,23 | |
| Noncash stock-based compensation | 11,330 | | |
| Write off of deferred loan costs | 4,614 | | |
| Other adjustments for non-cash items | 994 | 1,6 | |
| Deferred income taxes | (13,357) | 22,1 | |
| Changes in working capital | (27,680) | 3,34 | |
| Changes in other operating assets and liabilities | (21,631) | (32,7 | |
| Net cash (used in) provided by operating activities | (31,513) | 74,4 | |
| ash flows from investing activities: | | | |
| Purchases of fixed assets | (20,113) | (13,6 | |
| Acquisitions, net of cash received | (439) | (32,9 | |
| Proceeds from sale of fixed assets | 23 | 1 | |
| Net cash used in investing activities | (20,529) | (46,5 | |
| ash flows from financing activities: | | | |
| Borrowings under term credit facility | 100,000 | 55,0 | |
| Payments under term credit facility | (210,278) | (11,7 | |
| Proceeds from borrowings on revolving credit facilities | 28,185 | 58,0 | |
| Repayments of borrowings on revolving credit facilities | (28,158) | (86,5 | |
| Proceeds from the issuance of common stock, net of offering costs | 193,020 | | |
| Repurchases of common stock | (5,731) | | |
| Dividends paid to preferred shareholders | (38,546) | | |
| Other | (3,656) | (2,9 | |
| Net cash provided by financing activities | 34,836 | 11,7 | |
| Effect of exchange rates on cash | (2,125) | 7 | |
| (Decrease) increase in cash and cash equivalents | (19,331) | 40,4 | |
| Cash and cash equivalents, beginning of year | 48,093 | 7,6 | |
| Cash and cash equivalents, end of year | \$ 28,762 \$ | 48,0 | |

COLFAX CORPORATION Reconciliation of GAAP to non-GAAP Financial Measures

Unaudited

(dollars in thousands, except per share data)

| | Three Months Ended | | | | Year E | nde | ıded | |
|---|---------------------------|---------------------|----|---------------------|--------|---------------------|------|---------------------|
| | D | ecember 31, 2008 | D | ecember 31, 2007 | D | ecember 31, 2008 | D | ecember 31, 2007 |
| EBITDA | | | | | | | | |
| Net income (loss) | \$ | 10,379 | \$ | 28,992 | \$ | (571) | \$ | 64,882 |
| Interact average | | 2,138 | | 4,830 | | 11,822 | | 19,246 |
| Interest expense Provision for income taxes | | 9,210 | | 17,715 | | 5,438 | | 39,147 |
| Depreciation and amortization | | 3,443 | | 4,034 | | 14,788 | | 15,239 |
| | | 5,445 | _ | 4,034 | _ | 14,700 | _ | 15,259 |
| EBITDA | \$ | 25,170 | \$ | 55,571 | \$ | 31,477 | \$ | 138,514 |
| EBITDA margin | | 15.8% | _ | 38.7% | | 5.2% | | 27.4% |
| Adjusted EBITDA | | | | | | | | |
| | \$ | 10,379 | ¢ | 28.002 | ¢ | (571) | ¢ | 61 007 |
| Net income (loss) | Э | 10,379 | \$ | 28,992 | \$ | (571) | \$ | 64,882 |
| Interest expense | | 2,138 | | 4,830 | | 11,822 | | 19,246 |
| Provision for income taxes | | 9,210 | | 17,715 | | 5,438 | | 39,147 |
| Depreciation and amortization | | 3,443 | | 4,034 | | 14,788 | | 15,239 |
| IPO-related costs | | - | | - | | 57,017 | | - |
| Legacy legal adjustment | | - | | - | | 4,131 | | - |
| Due diligence costs | | - | | - | | 582 | | - |
| Asbestos liability and defense (income) costs | | 1,978 | | (31,946) | | (4,771) | | (63,978) |
| Asbestos coverage litigation expense | | 4,905 | | 5,314 | _ | 17,162 | | 13,632 |
| Adjusted EBITDA | \$ | 32,053 | \$ | 28,939 | S | 105,598 | \$ | 88,168 |
| Adjusted EBITDA margin | ÷ | 20.1% | | 20,355 | + | 17.5% | + | 17.4% |
| | | | | | | | | |
| Adjusted Net Income and Adjusted Earnings per Share | | | | | | | | |
| Net income (loss) | \$ | 10,379 | \$ | 28,992 | \$ | (571) | \$ | 64,882 |
| IPO-related costs | | - | | - | | 57,017 | | - |
| Legacy legal adjustment | | - | | - | | 4,131 | | - |
| Due diligence costs | | - | | - | | 582 | | - |
| Asbestos liability and defense (income) costs | | 1,978 | | (31,946) | | (4,771) | | (63,978) |
| Asbestos coverage litigation expense | | 4,905 | | 5,314 | | 17,162 | | 13,632 |
| Interest adjustment to effect IPO at beginning of period | | - | | 2,143 | | 2,302 | | 7,536 |
| Tax adjustment to 34% effective rate | | 210 | | 10,161 | _ | (22,201) | | 18,333 |
| Adjusted net income | \$ | 17,472 | \$ | 14,664 | \$ | 53,651 | \$ | 40,405 |
| Adjusted net income margin | | 11.0% | | 10.2% | | 8.9% | | 8.0% |
| | | 44.000.000 | | 44.000.000 | | 44.000.000 | | 11.000.000 |
| Shares outstanding at closing of IPO | ¢ | 44,006,026 | ¢ | 44,006,026 | ¢ | 44,006,026 | ¢ | 44,006,026 |
| Adjusted net income per share | \$ | 0.40 | \$ | 0.33 | \$ | 1.22 | \$ | 0.92 |
| Net income (loss) per share-basic and diluted in accordance with GAAP | \$ | 0.24 | \$ | 0.77 | \$ | (0.11) | \$ | 1.79 |
| | | | _ | | _ | ^ | | |
| Adjusted Operating Income | | | | | | | | |
| Operating income | \$ | 21,727 | \$ | 51,537 | \$ | 16,689 | \$ | 123,275 |
| IPO-related costs | | - | | - | | 57,017 | | - |
| Legacy legal adjustment | | - | | - | | 4,131 | | - |
| Due diligence costs | | - | | - | | 582 | | - |
| Asbestos liability and defense (income) costs | | 1,978 | | (31,946) | | (4,771) | | (63,978) |
| Asbestos coverage litigation expense | | 4,905 | | 5,314 | | 17,162 | | 13,632 |
| A divisted operating income | ¢ | 20 610 | ¢ | 24.005 | \$ | 00.910 | ¢ | 72 020 |
| Adjusted operating income | \$ | 28,610 | \$ | 24,905 | - | 90,810 15.0% | \$ | 72,929 |
| Adjusted operating income margin | | 18.0% | | 17.3% | | 13.0% | | 14.4% |

COLFAX CORPORATION Sales and Order Growth

Unaudited (amounts in millions)

| | | Sales | | | |
|---|-----------|--------|-----------|--------|---------|
| | | \$ | % | \$ | % |
| Three Months Ended December 31, 2007 | \$ | 143.7 | \$ | 156.5 | |
| Components of Growth: | | | | | |
| Organic growth from existing businesses | | 27.4 | 19.1% | (24.7) | (15.8)% |
| Acquisitions | | 0.8 | 0.6% | 3.1 | 2.0% |
| Foreign currency translation | | (12.6) | (8.8)% | (8.6) | (5.5)% |
| Total Growth | | 15.6 | 10.9% | (30.2) | (19.3)% |
| Three Months Ended December 31, 2008 | <u>\$</u> | 159.3 | <u>\$</u> | 126.3 | |
| | | Sales | | Order | s |
| | | \$ | % | \$ | % |
| Year Ended December 31, 2007 | \$ | 506.3 | \$ | 581.5 | |
| Components of Growth: | | | | | |
| Organic growth from existing businesses | | 70.2 | 13.9% | 40.9 | 7.0% |
| Acquisitions | | 5.5 | 1.1% | 11.7 | 2.0% |
| Foreign currency translation | | 22.9 | 4.5% | 35.1 | 6.1% |
| Total Growth | | 98.6 | 19.5% | 87.7 | 15.1% |
| Year Ended December 31, 2008 | <u>\$</u> | 604.9 | <u>\$</u> | 669.2 | |
| | 7 | | | | |

COLFAX CORPORATION Reconciliation of Projected 2009 Net Income Per Share to Adjusted Net Income Per Share Preliminary and Unaudited (amounts in dollars)

| | | EPS F | Range | |
|--|-----------|--------|-------|--------|
| Projected 2009 net income per share - fully diluted | \$ | 0.80 | \$ | 0.87 |
| Asbestos coverage litigation | | 0.28 | | 0.28 |
| Asbestos liability and defense costs | | 0.16 | | 0.16 |
| Income tax benefit at 32% | | (0.14) | | (0.14) |
| Projected 2009 adjusted net income per share - fully diluted | <u>\$</u> | 1.10 | \$ | 1.17 |
| Contact: Mitzi Reynolds, Vice President, Investor Relations | | | | |

Colfax Corporation 804-327-5689



February 20, 2009





The following information contains forward-looking statements, including forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements concerning Colfax's plans, objectives, expectations and intentions and other statements that are not historical or current facts. Forward-looking statements are based on Colfax's current expectations and involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such forward-looking statements. Factors that could cause Colfax's results to differ materially from current expectations include, but are not limited to factors detailed in Colfax's reports filed with the U.S. Securities and Exchange Commission as well as its Registration Statement on Form S-1 under the caption "Risk Factors". In addition, these statements are based on a number of assumptions that are subject to change. This presentation speaks only as of this date. Colfax disclaims any duty to update the information herein.





- Adjusted net income of \$17.5 million (40 cents per share), an increase of 19.1%
- Net sales of \$159.3 million, an increase of 10.9% (organic growth of 19.1%)
- Adjusted operating income of \$28.6 million, an increase of 14.9%
- Adjusted EBITDA of \$32.1 million, an increase of 10.8%
- Fourth quarter orders of \$126.3 million, a decrease of 19.3% (organic decrease of 15.8%)
- Record backlog of \$337.3 million







- Adjusted net income of \$53.7 million (\$1.22 per share), an increase of 32.8%
- Net sales of \$604.9 million, an increase of 19.5% (organic growth of 13.9%)
- Adjusted operating income of \$90.8 million, an increase of 24.5%
- Adjusted EBITDA of \$105.6 million, an increase of 19.8%
- Orders of \$669.2 million, an increase of 15.1% (organic growth of 7.0%)






Q4 2008 Earnings Call










































| | | Three Months Ended | | | D | elta |
|---|----|--------------------|------|---------------|------------------|----------------|
| | 12 | /31/2008 | _ 12 | /31/2007 | \$ | % |
| Orders | \$ | 126.3 | \$ | 156.5 | \$ (30.2) | -19.3% |
| Sales | \$ | 159.3 | \$ | 143.7 | \$ 15.6 | 10.9% |
| Gross Profit % of Sales | \$ | 57.8 36.3% | \$ | 49.2 34.2% | \$ 8.5 | 17.4% |
| SG&A Expense R&D Expense | \$ | 27.7 1.4 | \$ | 23.2 1.1 | \$ 4.5 0.3 | 19.4% 31.2% |
| Operating Expenses % of Sales | \$ | 29.1 18.3% | \$ | 24.3 16.9% | \$ 4.8 | 19.9% |
| Adjusted Operating Income % of Sales | \$ | 28.6 18.0% | \$ | 24.9 17.3% | \$ 3.7 | 14.9% |
| Adusted EBITDA % of Sales | \$ | 32.1 20.1% | \$ | 28.9 20.1% | \$ 3.1 | 10.8% |
| Adjusted Net Income % of Sales | \$ | 17.5 11.0% | \$ | 14.7 10.2% | \$ 2.8 | 19.1% |

Refer to Appendix for Non-GAAP reconciliation. Note: Dollars in millions.



| | | Year | Ende | d | | De | ta |
|--|----------|---------------------------------------|----------|--------------------------------------|----------|----------------------------|--------------------------------|
| | 12 | /31/2008 | 12 | /31/2007 | 2 | \$ | % |
| Orders | \$ | 669.2 | \$ | 581.5 | \$ | 87.7 | 15.1% |
| Sales | \$ | 604.9 | \$ | 506.3 | \$ | 98.6 | 19.5% |
| Gross Profit % of Sales | \$ | 217.2 35.9% | \$ | 175.6 34.7% | \$ | 41.6 | 23.7% |
| Adjusted SG&A Expense R&D Expense Operating Expenses % of Sales | \$ \$ | 120.5 <u>5.9</u> 126.4 20.9% | \$ \$ | 98.5 <u>4.2</u> 102.7 20.3% | \$ \$ | 22.0 <u>1.7</u> 23.7 | 22.4% <u>40.7%</u> 23.1% |
| Adjusted Operating Income % of Sales | \$ | 90.8 15.0% | \$ | 72.9 14.4% | \$ | 17.9 | 24.5% |
| Adusted EBITDA % of Sales | \$ | 105.6 17.5% | \$ | 88.2 17.4% | \$ | 17.4 | 19.8% |
| Adjusted Net Income % of Sales | \$ | 53.7 8.9% | \$ | 40.4 8.0% | \$ | 13.2 | 32.8% |

Refer to Appendix for Non-GAAP reconciliation. Note: Dollars in millions.





Statement of Cash Flows Summary (Preliminary & Unaudited)

| | Year Ended December 31, | | | | |
|--|----------------------------|---|----|--|--|
| | _ | 2008 | | 2007 | |
| Net (Loss) Income Non-Cash Expenses Change in Working Capital and Accrued Liabilities Other Total Operating Activities | \$ | (0.6) 18.4 (27.7) (21.6) (31.5) | \$ | 64.9 39.0 3.3 (32.7) 74.5 | |
| Capital Expenditures Acquisitions Proceeds from Sale of Fixed Assets | \$ | (20.1) (0.4) | \$ | (13.6) (33.0) 0.1 | |
| Total Investing Activities | \$ | (20.5) | \$ | (46.5) | |
| Net Borrowings Proceeds from IPO, Net of Offering Costs Dividends Paid Common Stock Repurchases Other Total Financing Activities | \$ | (110.3) 193.0 (38.5) (5.7) (3.7) 34.8 | \$ | 14.7 - - (<u>3.0)</u> 11.7 | |
| Effect of Exchange Rates on Cash | _ | (2.1) | | 0.8 | |
| (Decrease) Increase in Cash | | (19.3) | - | 40.5 | |
| Cash Beginning of Period | - | 48.1 | _ | 7.6 | |
| Cash End of Period | \$ | 28.8 | \$ | 48.1 | |

🛃 🌆 🕅 🏟 🗲 🎿 🎫 🐟 Zentr

Note: Dollars in millions.



- Debt to adjusted EBITDA < 1 times
- Approximately \$130 million available on revolver (expires in 2013)
- Approximately \$29 million in cash

Strong balance sheet and credit availability provide flexibility

(1) As of FYE 2008





| Rev | enue Ran | ge | | | | |
|------------------------------------|---|---------|-------------|------|-----------|--|
| 2009 Organic growth ⁽¹⁾ | 19 | 6 | to | | 3% | |
| 2009 Total | \$570 n | nillion | to | \$58 | 5 million | |
| | PS Range |) | | | | |
| 2009 Net income per shar | e | \$0.80 | | to | \$0.87 | |
| 2009 Adjusted net income per s | 09 Adjusted net income per share ⁽²⁾ \$1 | | | to | \$1.17 | |
| Assumptions | | | | | | |
| Asbestos coverage litigation | | \$1 | 2 mill | ion | | |
| Asbestos liability and defense | costs | \$7 | \$7 million | | | |
| Euro | | \$1. | .41 | | | |
| Tax rate | | 32 | % | | 0 | |
| Interest expense | | | millio | on | | |
| Incremental public company costs | | | .5 mil | lion | | |
| Outstanding shares | | 43 | .3 mil | lion | | |

 Excludes impact of foreign exchange rate fluctuations and acquisitions
 Excludes impact of asbestos coverage litigation and asbestos liability and defense costs (See Appendix for Non-GAAP reconciliation)

Adjusted EPS for 2009 of \$1.10 to \$1.17













Appendix





Adjusted net income, adjusted net income per share, adjusted operating income, EBITDA, adjusted EBITDA, adjusted selling, general and administrative expenses, organic sales growth and organic order growth are non-GAAP financial measures. Adjusted net income, adjusted net income per share, adjusted operating income and adjusted EBITDA exclude asbestos liability and defense cost (income) and asbestos coverage litigation expense, certain legacy legal charges, certain due diligence costs, as well as one time initial public offering-related costs. Adjusted selling, general and administrative expenses exclude certain legacy legal charges and certain due diligence costs. Adjusted net income also reflects interest expense as if the initial public offering (IPO) had occurred at the beginning of 2007 and presents income taxes at an effective tax rate of 34%. Adjusted net income per share assumes the 44,006,026 shares outstanding at the closing of the IPO to be outstanding since January 1, 2007. Projected adjusted net income per share excludes asbestos coverage litigation and asbestos liability and defense costs, and presents income tax benefit at 32%. Organic sales growth and organic order growth exclude the impact of acquisitions and foreign exchange rate fluctuations. These non-GAAP financial measures assist Colfax in comparing its operating performance on a consistent basis because, among other things, they remove the impact of changes in our capital structure and asset base, non-recurring items such as IPO-related costs, legacy asbestos issues (except in the case of EBITDA) and items outside the control of its operating management team.

Sales and order information by end market are estimates. We periodically update our customer groupings in order to refine these estimates. During the fourth quarter of 2008, reclassifications of previously reported amounts were made to conform to current period presentation. No changes have been made to total sales or orders.



Colfax Non-GAAP Reconciliation

| | Three Months Ended | | | Year Ended | | | | |
|---|--------------------|--------------------|----|--------------------|----|--------------------|----|--------------------|
| | Dee | cember 31, 2008 | De | cember 31, 2007 | De | cember 31, 2008 | De | cember 31, 2007 |
| EBITDA | | | | | | | | |
| Net income (loss) | \$ | 10,379 | \$ | 28,992 | \$ | (571) | \$ | 64,882 |
| Interest expense | | 2,138 | | 4,830 | | 11,822 | | 19,246 |
| Provision for income taxes | | 9,210 | | 17,715 | | 5,438 | | 39,147 |
| Depreciation and amortization | <u></u> | 3,443 | | 4,034 | | 14,788 | | 15,239 |
| EBITDA | \$ | 25,170 | \$ | 55,571 | \$ | 31,477 | \$ | 138,514 |
| EBITDA margin | | 15.8% | | 38.7% | | 5.2% | | 27.4% |
| Adjusted EBITDA | | | | | | | | |
| Net income (loss) | \$ | 10,379 | \$ | 28,992 | \$ | (571) | \$ | 64,882 |
| Interest expense | | 2,138 | | 4,830 | | 11,822 | | 19,246 |
| Provision for income taxes | | 9,210 | | 17,715 | | 5,438 | | 39,147 |
| Depreciation and amortization | | 3,443 | | 4,034 | | 14,788 | | 15,239 |
| IPO-related costs | | - | | - | | 57,017 | | - |
| Legacy legal adjustment | | - | | - | | 4,131 | | - |
| Due diligence costs | | - | | - | | 582 | | - |
| Asbestos liability and defense (income) costs | | 1,978 | | (31,946) | | (4,771) | | (63,978) |
| Asbestos coverage litigation expense | | 4,905 | | 5,314 | | 17,162 | | 13,632 |
| Adjusted EBITDA | \$ | 32,053 | \$ | 28,939 | \$ | 105,598 | \$ | 88,168 |
| Adjusted EBITDA margin | | 20.1% | | 20.1% | | 17.5% | | 17.4% |

Note: Dollars in thousands.



Colfax Non-GAAP Reconciliation

| | Three Months Ended | | | Year Ended | | | | |
|--|----------------------|-----------|----------------------|------------|----------------------|-----------|----------------------|-----------|
| | December 31, 2008 | | December 31, 2007 | | December 31, 2008 | | December 31, 2007 | |
| Adjusted Net Income and Adjusted Earnings per Share | | | | | | | | |
| Net income (loss) | \$ | 10,379 | \$ | 28,992 | \$ | (571) | \$ | 64,882 |
| IPO-related costs | | - | | - | | 57,017 | | - |
| Legacy legal adjustment | | - | | - | | 4,131 | | - |
| Due diligence costs | | - | | - | | 582 | | - |
| Asbestos liability and defense (income) costs | | 1,978 | | (31,946) | | (4,771) | | (63,978) |
| Asbestos coverage litigation expense | | 4,905 | | 5,314 | | 17,162 | | 13,632 |
| Interest adjustment to effect IPO at beginning of period | | - | | 2,143 | | 2,302 | | 7,536 |
| Tax adjustment to 34% effective rate | _ | 210 | _ | 10,161 | _ | (22,201) | | 18,333 |
| Adjusted net income | \$ | 17,472 | \$ | 14,664 | \$ | 53,651 | \$ | 40,405 |
| Adjusted net income margin | | 11.0% | | 10.2% | | 8.9% | | 8.0% |
| Shares outstanding at closing of IPO | 4 | 4,006,026 | 4 | 44,006,026 | 4 | 4,006,026 | 4 | 4,006,026 |
| Adjusted net income per share | \$ | 0.40 | \$ | 0.33 | \$ | 1.22 | \$ | 0.92 |
| Net income (loss) per share-basic | | | | | | | | |
| and diluted in accordance with GAAP | \$ | 0.24 | \$ | 0.77 | \$ | (0.11) | \$ | 1.79 |
| Adjusted Operating Income | | | | | | | | |
| Operating income | \$ | 21,727 | \$ | 51,537 | \$ | 16,689 | \$ | 123,275 |
| IPO-related costs | | - | | - | | 57,017 | | - |
| Legacy legal adjustment | | - | | - | | 4,131 | | - |
| Due diligence costs | | - | | - | | 582 | | - |
| Asbestos liability and defense (income) costs | | 1,978 | | (31,946) | | (4,771) | | (63,978) |
| Asbestos coverage litigation expense | | 4,905 | | 5,314 | | 17,162 | | 13,632 |
| Adjusted operating income | \$ | 28,610 | \$ | 24,905 | \$ | 90,810 | \$ | 72,929 |
| Adjusted operating income margin | | 18.0% | | 17.3% | | 15.0% | | 14.4% |

Note: Dollars in thousands, except per share amounts.



| | Three Mo | nths Ended | Year Ended | | | |
|--|--------------|--------------|--------------|-------------|--|--|
| | December 31, | December 31, | December 31, | December 31 | | |
| | 2008 | 2007 | 2008 | 2007 | | |
| Adjusted SG&A Expense | | | -00 | | | |
| Selling, general and administrative expenses | \$ 27,718 | \$ 23,223 | \$ 125,234 | \$ 98,500 | | |
| Legacy legal adjustment | - | - | 4,131 | - | | |
| Due diligence costs | - | - | 582 | - | | |
| | 8 | | 8 | 20 | | |
| Adjusted selling, general and administrative expense | es_\$ 27,718 | \$ 23,223 | \$ 120,521 | \$ 98,500 | | |



Note: Dollars in thousands.

Colfax Sales & Order Growth

| % | \$ | \$ 156.5 | % |
|--------|----------------|-------------|--|
| | \$ | 156.5 | |
| | | | |
| | | | |
| 19.1% | | (24.7) | (15.8%) |
| 0.6% | | 3.1 | 2.0% |
| (8.8%) | | (8.6) | (5.5%) |
| 10.9% | _ | (30.2) | (19.3%) |
| | \$ | 126.3 | |
| (| 0.6% (8.8%) | 0.6% (8.8%) | $\begin{array}{c cccc} 0.6\% & 3.1 \\ (8.8\%) & (8.6) \\ 10.9\% & (30.2) \\ \end{array}$ |

| | Sales | | | Orders | | | |
|---|-------|-------|-------|--------|-------|-------|--|
| | \$ | | % | \$ | | % | |
| Year Ended December 31, 2007 | \$ | 506.3 | | \$ | 581.5 | | |
| Components of Growth: | | | | | | | |
| Organic growth from existing businesses | | 70.2 | 13.9% | | 40.9 | 7.0% | |
| Acquisitions | | 5.5 | 1.1% | | 11.7 | 2.0% | |
| Foreign currency translation | | 22.9 | 4.5% | | 35.1 | 6.1% | |
| Total Growth | | 98.6 | 19.5% | | 87.7 | 15.1% | |
| Year Ended December 31, 2008 | | 604.9 | | \$ | 669.2 | | |

Note: Dollars in millions.



| | EPS Range | | | | | |
|--|-----------|--------|----|--------|--|--|
| Projected 2009 net income per share - fully diluted | \$ | 0.80 | \$ | 0.87 | | |
| Asbestos coverage litigation | | 0.28 | | 0.28 | | |
| Asbestos liability and defense costs | | 0.16 | | 0.16 | | |
| Income tax benefit at 32% | | (0.14) | | (0.14) | | |
| Projected 2009 adjusted net income per share - fully diluted | \$ | 1.10 | \$ | 1.17 | | |

